Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients

Transplantation

Volumn 76, Issue 4, 2003, Pages 631-636

  Jordan, Stanley C ^a,b   Vo, A ^a   Bunnapradist, S ^a   Toyoda, M ^a   Peng, A ^a   Puliyanda, D ^a   Kamil, E ^a   Tyan, D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIBODY; HLA ANTIGEN; IMMUNOGLOBULIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CADAVER DONOR; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVING DONOR; MALE; PRIORITY JOURNAL; SENSITIZATION; SURVIVAL RATE; TRANSPLANTATION;

ADOLESCENT; ADULT; AGED; CADAVER; CHILD; CHILD, PRESCHOOL; FEMALE; HEART TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; SURVIVAL RATE;

EID: 0042838104     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000080685.31697.FC     Document Type: Article

References (30)

1. United Network of Organ Sharing: Web address: http://www.unos.org. Accessed 2003.
2. USRDS Renal Data Systems Report. 2001.
3. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735-739.
4. Meier-Kriesche HU, Port FK, Ojo AO, et al. Effect of waiting time on renal transplant outcome. Kidney Int 2000; 58: 1311-1317.
5. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996 [see comments]. N Engl J Med 2000; 342: 605-612.
6. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345: 747-755.
7. Jordan SC, Tyan DB. Intravenous gamma globulin (IVIG) inhibits lymphocytotoxic antibody in vitro. J Am Soc Nephrol 1991; 2: 803.
8. Yadin O, Sekiya N, Ettenger R. Intravenous immunoglobulin (IVIG) reduces antibody responses in highly sensitized dialysis patients. J Am Soc Nephrol 1992; 3: 887.
9. Glotz D, Haymann JP, Niaudet P, et al. Successful kidney transplantation of immunized patients after desensitization with normal human polyclonal immunoglobulins. Transplant Proc 1995; 27: 1038-1039.
10. Glotz D, Haymann JP, Sansonetti N, et al. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg): a potential tool for transplantation of immunized patients. Transplantation 1993; 56: 335-337.
11. Tyan DB, Li VA, Czer L, et al. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994; 57: 553-562.
12. McIntyre JA, Higgins N, Britton R, et al. Utilization of intravenous immunoglobulin to ameliorate alloantibodies in a highly sensitized patient with a cardiac assist device awaiting heart transplantation: fluorescence-activated cell sorter analysis. Transplantation 1996; 62: 691-693.
13. De Marco T, Damon LE, Colombe B, et al. Successful immunomodulation with intravenous gamma globulin and cyclophosphamide in an alloimmunized heart transplant recipient. Heart Lung Transplant 1997; 16: 360-365.
14. Jordan SC, Quartel AW, Czer LS, et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 1998; 66: 800-805.
15. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887-895.
16. Casadei DH, del CRM, Opelz G, et al. A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation 2001; 71: 53-58.
17. Luke PP, Scantlebury VP, Jordan ML, et al. Reversal of steroid- and anti-lymphocyte antibody-resistant rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients. Transplantation 2001; 72: 419-422.
18. Jordan SC, Toyoda M. Treatment of autoimmune diseases and systemic vasculitis with pooled human intravenous immune globulin. Clin Exp Immunol 1994; 97(suppl 1): 31-38.
19. Toyoda M, Zhang XM, Petrosian A, et al. Inhibition of allospecific responses in the mixed lymphocyte reaction by pooled human gamma-globulin. Transpl Immunol 1994; 2: 337-341.
20. Toyoda M, Zhang X, Petrosian A, et al. Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by intravenous immunoglobulin. J Clin Immunol 1994; 14: 178-189.
21. Toyoda M, Pao A, Petrosian A, et al. Pooled human immune globulin (IVIG) inhibits the mixed lymphocyte reaction through modulation of surface molecules on antigen-presenting cells. Transplantation 1999; 67: S59.
22. Andersson U, Bjork L, Skansen-Saphir U, et al. Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev 1994; 139: 21-42.
23. Marchalonis JJ, Kaymaz H, Dedeoglu F, et al. Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain. Proc Natl Acad Sci USA 1992; 89: 3325-3329.
24. Daeron M. Fc receptor biology. Annu Rev Immunol 1997; 15: 203-234.
25. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of MG mediated through the inhibitory Fc receptor [see comments]. Science 2001; 291: 484-486.
26. Hurez V, Kaveri SV, Mouhoub A, et al. Anti-CD4 activity of normal human immunoglobulin G for therapeutic use. (Intravenous immunoglobulin, IVIg). Ther Immunol 1994; 1: 269-277.
27. Magee JC, Collins BH, Harland RC, et al. Immunoglobulin prevents complement-mediated hyperacute rejection in swine-to-primate xenotransplantation. J Clin Invest 1995; 96: 2404-2412.
28. Mauiyyedi S, Della P, Saidman S, et al. C4d deposits in peritubular capillaries (PTC) in chronic renal allograft rejection (CR). Lab Invest 1999; 79: 156.
29. Onitsuka S, Yamaguchi Y, Tanabe K, et al. Peritubular capillary deposition of C4d complement fragment in ABO-incompatibte renal transplantation with humoral rejection. Clin Transplant 1999; 13(suppl 1): 33-37.
30. Hariharan S, McBride MA, Cherikh WS, et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311-318.